VLPs are engineered particles that mimic key features of viruses without carrying a complete viral genome capable of producing infectious progeny. Their structure can be adapted to package and transport specific molecular cargo, allowing researchers to deliver genome-editing components directly into target cells. In the new work, the particles were used to deliver Cas9-based ribonucleoprotein complexes, in which the Cas9 nuclease is preassembled with a guide RNA. Once inside a cell, the guide RNA directs Cas9 to a matching genomic sequence, where the enzyme creates a targeted DNA break. Repair of that break can disrupt the gene, producing a knockout. Because the editing machinery is delivered as a transient protein-RNA complex rather than expressed continuously from a viral vector, the approach can limit the duration of Cas9 activity and reduce some of the complications associated with prolonged nuclease expression.

The researchers report that the VLP toolkit supports multiple CRISPR modalities in human monocytes, macrophages and dendritic cells. In addition to conventional gene knockout, the platform can deliver base-editing systems, which chemically convert individual DNA bases without generating the double-stranded breaks typically associated with standard Cas9 editing. Base editors can therefore create precise genetic substitutions, although their activity remains dependent on the location and sequence context of the target. The same delivery strategy was also used for epigenetic silencing. In this form of editing, CRISPR-guided regulatory proteins are directed to a gene’s control region and alter its transcriptional state without necessarily changing the underlying DNA sequence. Together, these capabilities give researchers a way to compare permanent gene disruption with more targeted nucleotide changes or reversible gene repression in the same broad class of immune cells.

The study further expands the system beyond editing existing genomic sequences. By combining VLP delivery with adeno-associated virus-mediated donor delivery, the researchers enabled site-specific insertion of large DNA sequences through homology-directed repair. In this configuration, the editing machinery creates a break at a chosen genomic site, while the AAV supplies a donor template containing the intended genetic payload and flanking regions that match the target locus. The cell can use these homologous sequences to copy the donor DNA into the genome. Such targeted integration is technically demanding in primary myeloid cells, which are generally resistant to manipulation and may respond strongly to DNA delivery. The combined platform could nonetheless support the introduction of larger genetic elements, a feature relevant to engineered-cell therapies that require the addition of receptors, regulatory circuits or other functional modules.

A central component of the work is SLICeVLP, a system developed to make pooled CRISPR screening possible in primary human macrophages. SLICeVLP separates two delivery tasks: guide RNA is supplied by a VPX-lentivirus, while Cas9 protein is delivered independently through engineered VLPs. This division allows the researchers to introduce guide sequences in a pooled format and then provide the nuclease as a controlled, transient editing reagent. In a pooled loss-of-function screen, thousands of cells can receive different guides targeting many genes, after which the population is exposed to a biological stimulus or sorted according to a measurable phenotype. Sequencing the guide identities in distinct cell populations reveals which genetic perturbations are associated with changes in that phenotype. The approach makes it possible to investigate gene function without having to create and maintain a separate engineered cell line for every candidate gene.

The researchers applied SLICeVLP to study the molecular controls governing tumor necrosis factor, or TNF, and CD80 expression in human macrophages. TNF is a potent inflammatory cytokine that helps coordinate immune responses but can also contribute to pathological inflammation when produced in excess. CD80 is a costimulatory molecule involved in communication between antigen-presenting cells and lymphocytes. By screening for genes that altered the levels of these markers, the team identified regulators of macrophage activation and inflammatory polarization. The work also incorporated Perturb-seq, a method that combines pooled genetic perturbations with single-cell RNA sequencing. Rather than measuring only one surface marker or secreted factor, Perturb-seq captures broad transcriptional changes in individual cells and links those expression profiles to the guide RNA that each cell received. This allows researchers to distinguish distinct cellular states and reconstruct how gene perturbations reshape immune programs.

The screen converged on TNFAIP3, which encodes the protein A20, as a central regulator of inflammatory polarization. A20 is widely recognized as a negative regulator of nuclear factor-κB-associated signaling, a pathway that controls the expression of many inflammatory genes. In the reported experiments, ablation of TNFAIP3 drove macrophages toward a strongly proinflammatory state. These cells were resistant to suppressive repolarization, suggesting that removing this regulatory brake did more than temporarily increase inflammatory gene expression. Instead, the perturbation appeared to stabilize a cellular program that could not readily be redirected by signals normally used to induce a less inflammatory phenotype. The result illustrates how pooled screening can expose control points that are difficult to identify through studies of individual genes or measurements limited to a single immune marker.

The researchers also examined the consequences of TNFAIP3 loss in chimeric antigen receptor macrophages, or CAR macrophages. These engineered cells are designed to recognize defined molecular targets through a synthetic receptor and then use macrophage effector functions to attack or process target material. In the study, removal of TNFAIP3 enhanced the cells’ cytotoxicity and reinforced their inflammatory behavior. The finding suggests that manipulating intrinsic signaling regulators could alter the activity of CAR macrophages after they encounter their targets. At the same time, the results highlight the balance required in therapeutic cell design: a stronger inflammatory and cytotoxic program may improve target-cell destruction, but persistent inflammatory activation could also affect safety, durability and interactions with surrounding tissues. The VLP platform provides a way to investigate these trade-offs systematically in primary human cells.

An important feature of the technology is that it was developed with the physiological properties of myeloid cells in mind. These cells are specialized to detect pathogens and foreign material, so delivery systems that work efficiently in more permissive cell types can provoke innate immune responses or impair survival in monocytes and macrophages. The study reports that VLP-mediated delivery maintained viability and preserved innate immune responsiveness, allowing the engineered cells to remain suitable for downstream functional testing. This distinction is essential for immunotherapy research because an editing method that changes a cell’s baseline activation state may produce misleading conclusions about gene function or therapeutic performance. By combining transient protein delivery, programmable guide RNAs and modular donor systems, the toolkit is intended to provide editing while retaining the biological behavior that makes primary myeloid cells valuable experimental and therapeutic models.

The platform does not eliminate the broader challenges of myeloid-cell engineering, including donor-to-donor variation, delivery efficiency across cell states and the need to assess unintended genomic or transcriptional effects. Nevertheless, the study establishes VLPs as a flexible delivery framework for knockout, base editing, epigenetic regulation and targeted DNA integration in primary human myeloid cells. Its use in pooled loss-of-function and Perturb-seq screens demonstrates how the same technology can move from molecular engineering to large-scale discovery. By connecting genetic perturbations with inflammatory phenotypes and therapeutic functions, the work offers a route to designing macrophage and other myeloid-cell therapies on the basis of systematic functional evidence rather than trial and error. The identification of TNFAIP3 as a key regulator of macrophage polarization further shows how these screens may reveal genetic interventions capable of reshaping the behavior of engineered immune cells.

Subject of Research: Virus-like particle-based CRISPR gene engineering and pooled functional-genomics screening in primary human myeloid cells.

Article Title: Virus-like particles enable targeted gene engineering and pooled CRISPR screening in primary human myeloid cells.

Article References: Jung, H., Devant, P., Ching, C. et al. “Virus-like particles enable targeted gene engineering and pooled CRISPR screening in primary human myeloid cells.” Nature Biotechnology (2026). https://doi.org/10.1038/s41587-026-03258-2

Image Credits: AI Generated

DOI: https://doi.org/10.1038/s41587-026-03258-2

Keywords: Virus-like particles, CRISPR, primary human myeloid cells, monocytes, macrophages, dendritic cells, VLP-mediated delivery, base editing, epigenetic silencing, homology-directed repair, AAV, SLICeVLP, Perturb-seq, TNFAIP3, CAR macrophages, immunotherapy.

Constrictive esophageal carcinoma is a daunting diagnosis given its tendency to narrow the esophagus, impairing swallowing and reducing life quality dramatically. Conventional treatments, which often involve surgery, chemotherapy, or radiation, bring considerable side effects and mixed outcomes. Gene therapy has long been a beacon of hope for targeted cancer treatment but delivering genetic material efficiently to the esophageal tissues has remained a challenge, primarily due to the harsh environment of the gastrointestinal tract and the esophagus’ complex structure. The new drinkable foam formulation is designed to surmount these barriers by providing a protective and adhesive matrix that optimizes gene delivery.

At the heart of this innovation lies a highly biocompatible foam that carries specially designed viral vectors engineered to deliver therapeutic genes directly to the malignant cells lining the esophagus. This foam can be ingested, transforming the conventional, invasive procedure into a non-invasive, well-tolerated therapeutic experience. The foam’s structural design ensures that it remains in contact with the esophageal lining long enough to facilitate robust gene transfer before it slowly dissolves or clears naturally through the digestive tract.

The mechanism by which this foam works is multifaceted. It combines adhesive polymers and surfactants that stabilize the viral particles and prevent premature degradation in the acidic environment of the stomach. By adhering to the esophageal mucosa, the foam maximizes local gene expression while minimizing systemic spread, potentially reducing off-target effects. This localized action is critical, as gene therapy must be both effective and safe in order to be viable for widespread clinical use.

Moreover, the viral vectors incorporated into the foam are finely tuned for high specificity to cancerous cells. The researchers utilized a selective promoter system activated only in tumor environments, ensuring that gene expression occurs precisely where it is needed. This smart vector design not only enhances the safety profile but also boosts the therapeutic efficacy by promoting apoptosis or other anti-cancer mechanisms selectively within the tumor microenvironment.

Clinical implications of this technology are profound. Moving from invasive gene therapy procedures to a drinkable foam could improve patient compliance and broaden access to gene therapies for esophageal carcinoma, especially in resource-limited settings. Patients suffering from constrictive symptoms may experience relief earlier due to the foam’s mechanical and biochemical actions, while the gene therapy works on rerouting the malignant progression.

Preclinical studies demonstrated encouraging results, with treated subjects showing significant restoration of esophageal patency and reduction in tumor burden. These results parallel an improvement in swallowing function noted during follow-ups, a direct measure of therapy’s practical benefits. Safety assessments indicated minimal inflammatory responses and no off-site transgene expression, highlighting the potential for translation into human trials.

Interestingly, beyond the pure therapeutic aspect, the foam’s formulation holds promise for adaptation to other gastrointestinal tract diseases where localized gene therapy could be transformative. Conditions such as Barrett’s esophagus, gastroesophageal reflux disease (GERD)-related complications, and even certain precancerous states could be future targets of this delivery technology.

The interdisciplinary team behind this innovation combined expertise in molecular genetics, biomaterials engineering, and clinical oncology. This convergence was essential for developing a formulation that not only delivers genes effectively but also navigates the complex biological barriers within the esophagus. Their rigorous approach involved iterative testing of foam compositions and viral vector modifications, underscoring the delicate balance between stability, biocompatibility, and gene transfer efficiency.

From a broader perspective, this technology highlights a paradigm shift in gene therapy delivery: moving away from traditional injections or endoscopic administrations toward more patient-friendly formats. If successful in clinical trials, such an approach could set a precedent for developing ‘oral’ formulations for other diseases requiring precision gene interventions, vastly expanding the reach of genetic medicine.

Ethical considerations also accompany this advancement. The drinkable foam presents a lower-risk alternative, possibly reducing complications related to gene therapy delivery. However, the long-term effects and potential immunogenicity require thorough investigation. Ensuring that gene editing or expression remains confined to target tissues is paramount to avoid unintended consequences.

Future directions outlined by the authors include refinement of viral vector targeting to further enhance tumor selectivity and foam bioadhesion properties to prolong esophageal retention. Scaling up the production under good manufacturing practice (GMP) conditions and designing clinical trials to evaluate efficacy and safety in diverse patient populations are crucial next steps.

In summary, the drinkable gene therapy foam introduced by Stephan and colleagues represents an elegant solution to a longstanding challenge in oncology and gene therapy. Its innovative delivery mode, combined with targeted genetic intervention, holds the promise of significantly improving outcomes for patients with constrictive esophageal carcinoma. As this technology advances toward clinical application, it is poised to transform the therapeutic landscape and inspire further innovations in gene delivery systems across medicine.

Subject of Research:
Article Title:
Article References:
Stephan, S.B., Cummings, C.L., Fitzgerald, K. et al. Drinkable gene therapy foam for the treatment of constrictive esophageal carcinoma. Gene Ther (2026). https://doi.org/10.1038/s41434-026-00592-7

Image Credits: AI Generated
DOI: 14 February 2026
Keywords:

Adeno-associated viruses represent one of the most promising vectors for gene therapy due to their ability to integrate into host genomes with minimal immunogenicity. They are particularly attractive because of their safety profile; they have been used extensively in preclinical studies and clinical trials. AAV9, a serotype within the AAV family, has gained attention for its capability to transduce various types of cells effectively, making it an optimal choice for targeting systemic diseases. The recent insights from Shahrukh and colleagues, however, point to variations in expression efficiency that may vary considerably by tissue type.

Through a meticulous analysis of existing studies, the researchers revealed that the efficiency of gene expression mediated by AAV9 is not uniform across different tissues in the primate model. This finding challenges the previously held assumption that AAV9 could be uniformly effective in advertising therapeutic genes to every part of the body. Instead, the research indicates that specific tissues may exhibit a higher proclivity to express transgenes delivered via AAV9, while others may demonstrate significantly lower efficiency. Understanding these differences is crucial in optimizing gene therapy protocols.

The study employed an exhaustive metadata analysis approach, analyzing a multitude of publications that investigated the impact of AAV9 on non-human primate models. By consolidating this data, the researchers were able to unify results and draw general conclusions about the behavior of AAV9 in various tissues. The comparative advantage of such an analysis lies in its ability to identify trends and inconsistencies that individual studies might overlook, providing a more comprehensive perspective on tissue-specific expression phenomena.

One of the standout findings relates to the differential performance of AAV9 in neuronal tissues versus other tissue types. The study suggests that neurons may harbor unique factors that facilitate enhanced transduction, leading to robust expression of transgenes. This understanding is particularly vital for developing effective gene therapies for neurological conditions, where precise targeting and expression of therapeutic genes are paramount. Conversely, other tissues like muscle or liver may not exhibit the same level of responsiveness, highlighting the need for tailored approaches based on the target tissue.

Additionally, factors such as the presence of specific receptors, the local microenvironment, and the underlying genetic variability among the subjects likely contributed to variations in expression levels. The research underscores the importance of considering these biological factors when designing AAV9-based gene therapies. Future therapies could potentially benefit from a tissue-specific optimization strategy, where the AAV vector and the gene of interest are paired with particular delivery methods that consider the unique biological characteristics of target tissues.

Among the noteworthy implications of this work lies its potential influence on the translation of gene therapies into effective treatments. By addressing tissue-specific challenges in transgene expression, this research paves the way for precision medicine approaches, enabling clinicians to tailor therapies towards individual patient needs based on the specific characteristics of the affected tissue. As the field of gene therapy continues to evolve, such targeted strategies could bolster the success rates of therapeutic interventions.

Understanding the details of AAV9’s interaction with various tissues can also guide researchers in selecting optimal administration routes for different applications. For instance, the choice of whether to administer AAV9 systemically or locally could be informed by how effectively different tissues respond to the viral vector. Such strategic insights could lead to enhanced efficacy and minimized adverse effects, thus improving the overall therapeutic window for gene therapies.

Importantly, the findings presented in this study will contribute to a more knowledgeable framework for evaluating AAV9’s utility in clinical trials. By providing a foundational understanding of how expression efficiency may fluctuate depending on the target tissue, future trials can be better designed to assess not only the safety and efficacy of AAV9-based therapies but also to explore the biological mechanisms that underpin these variations in expression.

As researchers continue to dissect the intricate behaviors of AAV vectors, particularly AAV9, it is imperative that they account for the diversity encountered in different biological contexts. Future experiments and clinical trials should focus on elucidating the mechanisms responsible for the observed tissue-specific expression variations, fostering a deeper understanding of how viral vectors function across varied physiological landscapes.

The comprehensive analysis pioneered by Shahrukh et al. serves as a clarion call to the scientific community to acknowledge and delve deeper into the complexities presented by viral gene delivery systems. As we inch closer to realizing the full potential of gene therapy, it becomes increasingly clear that a one-size-fits-all approach is inadequate to meet the demands of diverse diseases, calling for innovations that capitalize on the distinct advantages presented by various tissues and biological conditions.

Furthermore, the collaboration between multidisciplinary teams, including geneticists, molecular biologists, and clinicians, will be vital to move this field forward. Discussions surrounding the clinical implications of these findings should foster a spirit of collaboration that bridges the gap between laboratory discoveries and clinical applications, thus ensuring that emerging therapies can be rapidly developed and implemented in patient care.

In conclusion, the assessment of AAV9’s performance in non-human primates, illuminated by the metadata analysis conducted by Shahrukh and coworkers, unveils a landscape rich with potential for advancement in gene therapy techniques. By acknowledging and addressing tissue-specific expression challenges, researchers and clinicians alike can aspire to harness the full power of AAV vectors to transform the treatment paradigms of complex genetic diseases, thereby enriching the lives of patients with previously untreatable conditions.

Through this rigorous investigation into the nuances of gene delivery systems, the groundwork is laid for a new era of precision gene therapies aimed at crafting tailored solutions for individual patients. A deeper understanding of tissue interactions with AAV9 not only serves to enhance therapeutic strategies but also catalyzes innovations that may resonate through the broader landscape of medical biology.

Ultimately, as we look ahead, the revelations offered by this research may reshape our approach to gene therapy, marking a paradigm shift that can unlock unprecedented treatment avenues rooted in the fundamental biology of tissues. The journey towards effective gene therapy efficacy and safety continues, fueled by ongoing inquiry and discovery, now further inspired by the critical insights of AAV9’s intrinsic behaviors across the living systems we aim to serve.

Subject of Research: Tissue-specific variation in expression efficiency of AAV9 in non-human primates.

Article Title: Metadata assessment of non-human primate studies of AAV9 uncovers potential tissue specific variation in expression efficiency.

Article References:

Shahrukh, M., Sweeney, J.R., del Rio, T. et al. Metadata assessment of non-human primate studies of AAV9 uncovers potential tissue specific variation in expression efficiency.
Gene Ther (2026). https://doi.org/10.1038/s41434-025-00589-8

Image Credits: AI Generated

DOI: https://doi.org/10.1038/s41434-025-00589-8

Keywords: AAV9, gene therapy, non-human primates, expression efficiency, tissue specificity, precision medicine.